• Klíčová slova
• Varilrix, Varivax, Priorix Tetra, ProQuad,
• MeSH
• dítě MeSH
• herpes zoster etiologie   MeSH
• kontraindikace léčebného výkonu MeSH
• lidé MeSH
• plané neštovice * epidemiologie   komplikace   mortalita   prevence a kontrola   MeSH
• postexpoziční profylaxe metody   MeSH
• rizikové faktory MeSH
• směrnice pro lékařskou praxi jako téma * MeSH
• vakcína proti planým neštovicím aplikace a dávkování   terapeutické užití   MeSH
• vakcinace * metody   MeSH
• virus varicella zoster MeSH
• Check Tag
• dítě MeSH
• lidé MeSH

• MeSH
• acyklovir farmakologie   terapeutické užití   MeSH
• dítě MeSH
• dospělí MeSH
• hepatorenální syndrom etiologie   MeSH
• imunokompromitovaný pacient imunologie   MeSH
• koagulopatie etiologie   imunologie   MeSH
• lidé MeSH
• plané neštovice * komplikace   prevence a kontrola   MeSH
• vakcína proti planým neštovicím MeSH
• virová pneumonie etiologie   farmakoterapie   MeSH
• virus varicella zoster * patogenita   MeSH
• Check Tag
• dítě MeSH
• dospělí MeSH
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• kazuistiky MeSH

• Klíčová slova
• Shingrix,
• MeSH
• acyklovir farmakologie   terapeutické užití   MeSH
• DNA vakcíny farmakologie   terapeutické užití   MeSH
• ganglia virologie   MeSH
• herpes zoster ophthalmicus * komplikace   MeSH
• herpeszosterová encefalitida * diagnóza   farmakoterapie   MeSH
• latence viru MeSH
• lidé MeSH
• magnetická rezonance intervenční MeSH
• nemoci cév etiologie   MeSH
• senioři MeSH
• vakcína proti pásovému oparu MeSH
• virus varicella zoster MeSH
• Check Tag
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• Publikační typ
• kazuistiky MeSH

The Ramsay-Hunt syndrome results from reactivation of the varicella-zoster virus at the geniculate ganglion level. The syndrome is characterized by a combination of symptoms such as ipsilateral facial paralysis, otalgia, and vesicles near the ear and auditory canal. The gold standard in the treatment of Ramsay-Hunt syndrome remains the combination of antiviral therapy with corticosteroids and adequate analgesic therapy. We present a case of a 45-year-old patient with severe form of atopic dermatitis, who developed this syndrome during treatment with dupilumab. The risks and benefits of dupilumab treatment in this patient were considered. Because both bronchial asthma and atopic dermatitis worsened when dupilumab was discontinued, it was indicated to continue this therapy with low-dose of acyclovir.

• MeSH
• acyklovir terapeutické užití   MeSH
• antivirové látky terapeutické užití   škodlivé účinky   MeSH
• atopická dermatitida * farmakoterapie   MeSH
• bronchiální astma farmakoterapie   MeSH
• herpes zoster ušní * farmakoterapie   diagnóza   MeSH
• humanizované monoklonální protilátky * terapeutické užití   škodlivé účinky   MeSH
• lidé středního věku MeSH
• lidé MeSH
• virus varicella zoster MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• dopisy MeSH
• kazuistiky MeSH

Chronic hepatitis B (CHB) remains a major public health problem worldwide, with limited treatment options, but inducing an antiviral response by innate immunity activation may provide a therapeutic alternative. We assessed the cytokine-mediated anti-hepatitis B virus (HBV) potential for stimulating the cyclic GMP-AMP synthase-stimulator of interferon genes (STING) pathway using STING agonists in primary human hepatocytes (PHH) and nonparenchymal liver cells (NPCs). The natural STING agonist, 2',3'-cyclic GMP-AMP, the synthetic analogue 3',3'-c-di(2'F,2'dAMP), and its bis(pivaloyloxymethyl) prodrug had strong indirect cytokine-mediated anti-HBV effects in PHH regardless of HBV genotype. Furthermore, STING agonists induced anti-HBV cytokine secretion in vitro, in both human and mouse NPCs, and triggered hepatic T cell activation. Cytokine secretion and lymphocyte activation were equally stimulated in NPCs isolated from control and HBV-persistent mice. Therefore, STING agonists modulate immune activation regardless of HBV persistence, paving the way toward a CHB therapy.

• MeSH
• cytokiny metabolismus   MeSH
• hepatitida B * farmakoterapie   MeSH
• hepatocyty MeSH
• herpesvirus B * MeSH
• interferony metabolismus   MeSH
• lidé MeSH
• myši MeSH
• zvířata MeSH
• Check Tag
• lidé MeSH
• myši MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH

The herpes simplex virus (HSV) is a double-stranded DNA human virus that causes persistent infections with recurrent outbreaks. HSV exists in two forms: HSV-1, responsible for oral herpes, and HSV-2, primarily causing genital herpes. Both types can lead to significant complications, including neurological issues. Conventional treatment, involving acyclovir and its derivatives, faces challenges due to drug resistance. This underscores the imperative for continual research and development of new drugs, with a particular emphasis on exploring the potential of natural antivirals. Flavonoids have demonstrated promise in combating various viruses, including those within the herpesvirus family. This review, delving into recent studies, reveals the intricate mechanisms by which flavonoids decode their antiviral capabilities against HSV. By disrupting key stages of the viral life cycle, such as attachment to host cells, entry, DNA replication, latency, and reactivation, flavonoids emerge as formidable contenders in the ongoing battle against HSV infections.

• MeSH
• antivirové látky farmakologie   terapeutické užití   MeSH
• flavonoidy farmakologie   terapeutické užití   MeSH
• herpes simplex * farmakoterapie   MeSH
• lidé MeSH
• lidský herpesvirus 1 * fyziologie   MeSH
• stadia vývoje MeSH
• zvířata MeSH
• Check Tag
• lidé MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• přehledy MeSH

• MeSH
• aktivace viru fyziologie   MeSH
• analýza dat MeSH
• herpes zoster * epidemiologie   farmakoterapie   komplikace   prevence a kontrola   MeSH
• hlášení nemocí * MeSH
• lidé MeSH
• rizikové faktory MeSH
• rutinně sbírané zdravotní údaje MeSH
• vakcinace MeSH
• virus varicella zoster patogenita   MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• práce podpořená grantem MeSH
• Geografické názvy
• Česká republika MeSH

• MeSH
• aktivace viru fyziologie   MeSH
• herpes zoster * epidemiologie   komplikace   prevence a kontrola   MeSH
• imunogenicita vakcíny MeSH
• lidé MeSH
• rizikové faktory MeSH
• senioři MeSH
• vakcína proti pásovému oparu * ekonomika   farmakologie   imunologie   klasifikace   MeSH
• vakcinace ekonomika   MeSH
• virus varicella zoster patogenita   MeSH
• Check Tag
• lidé MeSH
• senioři MeSH
• Publikační typ
• práce podpořená grantem MeSH
• přehledy MeSH
• Geografické názvy
• Česká republika MeSH

PURPOSE: The combination of talimogene laherparepvec (T-VEC) and pembrolizumab previously demonstrated an acceptable safety profile and an encouraging complete response rate (CRR) in patients with advanced melanoma in a phase Ib study. We report the efficacy and safety from a phase III, randomized, double-blind, multicenter, international study of T-VEC plus pembrolizumab (T-VEC-pembrolizumab) versus placebo plus pembrolizumab (placebo-pembrolizumab) in patients with advanced melanoma. METHODS: Patients with stage IIIB-IVM1c unresectable melanoma, naïve to antiprogrammed cell death protein-1, were randomly assigned 1:1 to T-VEC-pembrolizumab or placebo-pembrolizumab. T-VEC was administered at ≤ 4 × 106 plaque-forming unit (PFU) followed by ≤ 4 × 108 PFU 3 weeks later and once every 2 weeks until dose 5 and once every 3 weeks thereafter. Pembrolizumab was administered intravenously 200 mg once every 3 weeks. The dual primary end points were progression-free survival (PFS) per modified RECIST 1.1 by blinded independent central review and overall survival (OS). Secondary end points included objective response rate per mRECIST, CRR, and safety. Here, we report the primary analysis for PFS, the second preplanned interim analysis for OS, and the final analysis. RESULTS: Overall, 692 patients were randomly assigned (346 T-VEC-pembrolizumab and 346 placebo-pembrolizumab). T-VEC-pembrolizumab did not significantly improve PFS (hazard ratio, 0.86; 95% CI, 0.71 to 1.04; P = .13) or OS (hazard ratio, 0.96; 95% CI, 0.76 to 1.22; P = .74) compared with placebo-pembrolizumab. The objective response rate was 48.6% for T-VEC-pembrolizumab (CRR 17.9%) and 41.3% for placebo-pembrolizumab (CRR 11.6%); the durable response rate was 42.2% and 34.1% for the arms, respectively. Grade ≥ 3 treatment-related adverse events occurred in 20.7% of patients in the T-VEC-pembrolizumab arm and in 19.5% of patients in the placebo-pembrolizumab arm. CONCLUSION: T-VEC-pembrolizumab did not significantly improve PFS or OS compared with placebo-pembrolizumab. Safety results of the T-VEC-pembrolizumab combination were consistent with the safety profiles of each agent alone.

• MeSH
• dvojitá slepá metoda MeSH
• lidé MeSH
• lidský herpesvirus 1 * MeSH
• melanom * farmakoterapie   MeSH
• onkolytická viroterapie * metody   MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• klinické zkoušky, fáze I MeSH
• klinické zkoušky, fáze III MeSH
• multicentrická studie MeSH
• práce podpořená grantem MeSH
• randomizované kontrolované studie MeSH

• MeSH
• herpes zoster * etiologie   komplikace   prevence a kontrola   MeSH
• lidé MeSH
• plané neštovice * epidemiologie   prevence a kontrola   MeSH
• postherpetická neuralgie diagnóza   MeSH
• vakcína proti pásovému oparu aplikace a dávkování   terapeutické užití   MeSH
• vakcína proti planým neštovicím aplikace a dávkování   terapeutické užití   MeSH
• virus varicella zoster MeSH
• Check Tag
• lidé MeSH